Viva Biotech Holdings Group, a global leader in drug research, development and manufacturing services, has established a new branch in Boston, USA—marking a significant step forward in the company’s global expansion strategy.
 
The company aims to further enhance and deepen its international collaboration networks, providing comprehensive one-stop CRO-CMC/CDMO services—from drug discovery and preclinical development to commercial manufacturing—for clients worldwide.
 
The new Boston branch is situated in Cambridge, Massachusetts, placing it at the forefront of global biopharma innovation. Surrounded by world-class research institutions like Harvard University and Massachusetts Institute of Technology, as well as being the home to numerous biotech giants and innovative startups, this location offers access to cutting-edge scientific advancements and collaborative opportunities.
 
The Boston branch will serve as a crucial hub within Viva Biotech’s global network, connecting operations in China, the United States, the United Kingdom, Europe, and other regions. Together, these interconnected entities will form an efficient global operational system, poised to respond to the evolving landscape of drug discovery and development, as well as the increasingly diverse needs of clients.
 
Dr. Cheney Mao, Chairman and CEO of Viva Biotech stated: “Boston is a critical hub for global biopharmaceutical innovation and has always been a key focus of Viva Biotech’s globalization strategy. Over the years, we have cultivated the brand awareness in the region through our drug discovery services. Moving forward, we will further expand our CRO and CDMO business, strengthening early-stage project capabilities to drive future growth. It is our crucial strategy to establish the branch in Boston to deepen our international markets presence and enhance our global competitiveness. We are building a more open and collaborative global service network to provide flexible and efficient comprehensive solutions for our partners. Looking ahead, Viva Biotech will continue to advance its globalization strategy, enhancing its one-stop drug discovery and manufacturing capabilities to contribute to the development of the global biopharmaceutical industry.”